Business Wire

IMPROVE

28.9.2021 14:03:13 CEST | Business Wire | Press release

Share
To Support European Healthcare Systems Post COVID-19, ImPrOve Experts Call for Improved Perioperative Monitoring to Optimise Patient Safety

The Improving Patient Outcomes (ImPrOve) Think Tank, a group of anaesthetists, surgeons and patient representatives, today launched its European Report to address a serious public health issue – death and serious complication rates in the 30-days after high-risk surgery remain high.i In an effort to improve patient safety and outcomes, the Report calls for better physician training on the latest guidelines, funding for modern digital monitoring, greater use of data from modern technologies in health policies and the right for patients to be involved in dialogue about the management of their procedure.

In Europe, 2.4 million patients undergo high-risk surgery every year.ii,iii Evidence from the UK suggests that 80% of postoperative deaths occur in a 10% sub-population of high-risk patients. If this trend continued at a European level, potentially 192,000 will die in the 30-day period after surgery.i While there are many challenges in high-risk surgery, the most alarming complication for the ImPrOve Think Tank is haemodynamic instability, manifested as drops in blood pressure, and known as IOH.i

During high-risk surgery it is vital that blood continues to flow to organs. IOH is common during surgery under general anaesthesia, occurring in up to 99% of patients.i It has the potential to cause tissue damage in any vital organ, but the heart and kidneys are most affected. Recent studies show associations between IOH and increased risk of acute kidney injury (AKI) and myocardial injury iv,v – the leading cause of post-operative mortality.

Postsurgical patients with AKI and myocardial injury stay longer in hospital, have higher readmission rates, and cost more to care for.iv The subsequent financial impact of this also has a significant impact on European healthcare systems. However, if haemodynamic instability is effectively monitored and prevented, these serious complications can be avoided, and patient outcomes can be significantly improved.

“Our mission is to work collaboratively with patient representatives, clinicians and policy makers to improve perioperative patient safety and experience with the help of advanced haemodynamic monitoring technologies”, commented Professor Olivier Huet, ImPrOve Chair and Professor of Anaesthesia and Intensive Care Medicine. “Major gaps still exist in reducing the risk of complications after high-risk surgery across European hospitals, working together is therefore imperative. All stakeholders need to be onboard so that we can create change and address the calls to action.”

By 2050, it is predicted that 1 in 4 people could be over 65.vi With haemodynamic instability reported as high as 83% in more senior patients,vii the ImPrOve Think Tank believe it will be a likely cause of a significant proportion of modifiable postoperative mortality and morbidity in Europe.

“Patients are often unaware of the risks of not receiving innovative digital monitoring technology, so they may not ask for the best perioperative management”, said Ms Luciana Valente, International Relations Manager at SIHA, Italy, and member of the Think Tank. “It is essential that patients are better informed of the key risks associated with their procedure and aware that the use of innovative digital monitoring, and other actions will be taken to mitigate these risks. The more a patient is invested in a procedure, the better the outcomes will be.”

For further information and to download ‘Improving patient safety: why perioperative care and effective monitoring matters” please visit www.improvethinktank.org

References


i Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C et al . Mortality after surgery in Europe: a 7-day cohort study. Lancet. 2021; Sep 22;380(9847):1059-65. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61148-9/fulltext [accessed July 2021].

ii Preoperative Score to Predict Postoperative Mortality – POSPOM Edward’s Presentation

iii Ghaferi, et al. Variation in Hospital Mortality Associated with Inpatient Surgery. N Engl J Med, 2009.

iv Keuffel EL, Rizzo J, Stevens M, Gunnarsson C, Maheshwari K. Hospital costs associated with intraoperative hypotension among non-cardiac surgical patients in the US: a simulation model. J Med Econ. 2019 Jul;22(7):645-651. Available at: https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1591147 [accessed July 2021]

v Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. Br J Anaesth. 2018 Oct;121(4):706-721. Available at: https://bjanaesthesia.org/article/S0007-0912(18)30376-3/fulltext . [accessed July 2021].

vi United Nations. Ageing. 2019. Available at: https://www.un.org/en/sections/issues-depth/ageing/ [accessed July 2021]

vii Wickham A, Highton D, Martin D, The Pan London Perioperative Audit and Research Network. Care of elderly patients: a prospective audit of the prevalence of hypotension and the use of BIS intraoperatively in 25 hospitals in London. Perioper Med (Lond). 2016; 5: 12. Available at: (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882849/ ) [accessed July 2021].

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 07:00:00 CET | Press release

Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports

Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 07:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re

Andersen Consulting styrker sin platform med samarbejdsvirksomheden Ambit Iberia12.3.2026 05:55:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med Ambit Iberia, et konsulentfirma, der specialiserer sig i digitale og regulatoriske løsninger til life science-sektoren. Ambit Iberia, der blev stiftet i 2003, har hovedsæde i Spanien og leverer integrerede løsninger inden for rådgivning, teknologi og rekruttering til medicinal-, bioteknologi- og medtechvirksomheder. Virksomheden hjælper kunder med at opfylde skiftende standarder for kvalitet, compliance og lovgivning gennem ydelser, der spænder over regulatoriske anliggender, dataintegritet, validering af it-systemer og digital transformation. Med mere end 20 års brancheerfaring tilbyder Ambit Iberia også ydelser inden for human capital og executive search, der forbinder organisationer med specialiserede fagfolk og topledertalenter, hvilket øger effektiviteten og fremmer bæredygtig vækst i et stærkt reguleret miljø. "Vores fokus har altid været at levere speciali

EIG’s MidOcean Energy to Acquire Additional Gorgon LNG Interest from JERA; Parties Explore Strategic Alliance12.3.2026 03:14:00 CET | Press release

Transaction increases MidOcean’s equity exposure to premier Australian LNG project Adds incremental uncontracted LNG volumes, enhancing portfolio optimization and marketing flexibility Planning future collaborations, exploring further transactions and opportunities with JERA across other assets globally with the aim of creating a future strategic alliance MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced it has entered into definitive agreements with JERA Co., Inc. (“JERA”) to acquire JERA Gorgon Pty Ltd, which holds JERA’s 0.417% interest in the Gorgon LNG project. MidOcean is an existing participant in the Gorgon LNG project, and this transaction increases MidOcean’s interest in Gorgon to 1.417%. The transaction perimeter also includes JERA’s 0.735% interest in the Ichthys LNG project. Subject to the satisfaction of relevant conditions precedent, the interests in Gorgon and Ichthys will be sold to MidOcean, and then the Ich

DCX Launches Comprehensive ECDU Portfolio – Enterprise-Class Coolant Distribution Units From 600 kW to 2.6 MW11.3.2026 16:34:00 CET | Press release

DCX Liquid Cooling Systems today unveiled its new ECDU (Enterprise Coolant Distribution Unit) platform, a family of three purpose-built CDU models that deliver real cooling capacities from 600 kW to 2.6 MW in industry-standard rack and in-row footprints. The portfolio has been engineered specifically for the accelerating transition to direct-to-chip liquid cooling in high-density enterprise, colocation, cloud, and hyperscale AI environments where thermal stability, uptime, and cost-efficiency are non-negotiable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311214891/en/ DCX ECDU, the new generation of Enterprise Coolant Distribution Units dedicated to HPC and AI deployments. The lineup consists of: Enterprise ECDU 1380/2600 V1 - Delivers 1.38–2.6 MW of actual cooling capacity (based on real-world secondary-loop conditions). Single-pump configuration reaches flow rates up to 3,333 liters per minute (lpm). Mission Critica

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye